| Insurance Industry | Financials Sector | Mr. Ronan Boulme CEO | XFRA Exchange | FR001400AHX6 ISIN |
| France Country | 20 Employees | 3 Jul 2026 Last Dividend | 18 May 2022 Last Split | - IPO Date |
ABL Diagnostics Société anonyme, originally known as Etablissements Fauvet Girel, is a renowned provider of molecular biology assays and comprehensive solutions primarily used for molecular detection through polymerase chain reaction (PCR) and DNA sequencing technologies. With its headquarters located in Woippy, France, the company operates both domestically and internationally. It specializes in genotyping for a range of viruses, including SARS CoV-2 and HIV, through next-generation sequencing (NGS) and Sanger sequencing methods. In April 2022, it transitioned its name to ABL Diagnostics Société anonyme, reflecting its affiliation as a subsidiary with Advanced Biological Laboratories (ABL) S.A. ABL Diagnostics takes pride in serving a diverse clientele that encompasses academic clinical pathology labs, private reference labs, and research institutions, selling its products directly and through a vast distributor network.
The company's portfolio is vast, encompassing a variety of diagnostics and research solutions, which include: